Inside the Gene Therapy for Ophthalmic Disorders Summit: What We Learned and Why It Matters for Families Facing Vision Loss

Earlier this month, our team attended the Gene Therapy for Ophthalmic Disorders Summit , a gathering of leading scientists, clinicians, biotech innovators, and regulatory experts who are shaping the future of treatments for inherited retinal diseases (IRDs). While not every session directly applied to Bardet-Biedl Syndrome (BBS) or retinitis pigmentosa (RP), many of the discussions were deeply relevant to what families in our community are hoping, waiting, and fighting for: safe, effective treatments delivered as quickly as possible. This blog is the first in a three-part series breaking down the most meaningful insights from the summit — and explaining what they really mean for you. A Field Moving Faster Than Ever One thing was unmistakable at this year's summit: Gene therapy for vision loss is accelerating. Researchers emphasized: Faster regulatory pathways New delivery technologies More flexible clinical trial designs Greater acceptance of modern functional vision endpoints A growing global commitment to rare eye diseases For families navigating BBS or RP — diseases that steal vis